Jiangsu gdk Biotechnology Co., Ltd.

Shanghai Stock Exchange 688670.SS

Jiangsu gdk Biotechnology Co., Ltd. Gross Profit for the year ending December 31, 2023: USD 14.75 M

Jiangsu gdk Biotechnology Co., Ltd. Gross Profit is USD 14.75 M for the year ending December 31, 2023, a -62.00% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Jiangsu gdk Biotechnology Co., Ltd. Gross Profit for the year ending December 31, 2022 was USD 38.82 M, a -26.39% change year over year.
Jiangsu gdk Biotechnology Co., Ltd. Gross Profit for the year ending December 31, 2021 was USD 52.74 M, a -33.21% change year over year.
Jiangsu gdk Biotechnology Co., Ltd. Gross Profit for the year ending December 31, 2020 was USD 78.96 M, a 870.56% change year over year.
Jiangsu gdk Biotechnology Co., Ltd. Gross Profit for the year ending December 31, 2019 was USD 8.14 M, a 365.59% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Shanghai Stock Exchange: 688670.SS

Jiangsu gdk Biotechnology Co., Ltd.

CEO	Mr. Jun Yu
IPO Date	Aug. 2, 2021
Location	China
Headquarters	12 Yujin Road
Employees	451
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Jiangsu gdk Biotechnology Co., Ltd., a biological company, engages in the scientific research, production, operation, and service of human vaccines. The company offers quadrivalent influenza virus split and lyophilized human rabies vaccines. Its product pipeline has coverage for the prevention of principal infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. The company was founded in 2008 and is based in Taizhou, China.

Key trends

Past 5 years